UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009475 |
|---|---|
| Receipt number | R000011123 |
| Scientific Title | Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial |
| Date of disclosure of the study information | 2012/12/04 |
| Last modified on | 2012/12/04 09:56:47 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial
Acronym
Clinical trial for the incidence of gastrointestinal lesions by selective COX-2 inhibitor
Scientific Title
Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial
Scientific Title:Acronym
Clinical trial for the incidence of gastrointestinal lesions by selective COX-2 inhibitor
Region
| Japan |
Condition
Condition
NSAID induced gastrointestinal mucosal lesions
Classification by specialty
| Gastroenterology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assess the esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib, in healthy volunteers
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The numbers of small intestinal mucosal breaks evaluated by capsule endoscopy
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Single blind -investigator(s) and assessor(s) are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
Famotidine 20 mg/day b.i.d. and loxoprofen 180 mg/day t.i.d for 2 weeks by oral administration
Interventions/Control_2
Famotidine 20 mg/day b.i.d. and etodolac 400 mg/day b.i.d for 2 weeks by oral administration
Interventions/Control_3
Famotidine 20 mg/day b.i.d. and celecoxib 200 mg/day b.i.d for 2 weeks by oral administration
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Healthy adults who are 20 years or older, and less than 80 years of age at the time of obtaining informed consent
2) Subjects from whom fully informed written consent based on their full understanding and their own voluntary will was obtained at the commencement of this study
Key exclusion criteria
1) Subjects who have active peptic ulcer or gastrointestinal bleeding and need endoscopic treatment immediately
2) Subjects with significant hepatic disease, renal disease, heart disease or respiratory disease
3) Subjects with a history of gastrointestinal surgery other than appendectomy
4) Subjects orally taking or planning to orally take drug other than loxoprofen, etodolac, celecoxib or famotidine
5) Subjects with alcohol or chemical dependencies
6) Subjects with a history of intestinal obstruction, or person with suspected gastrointestinal
obstruction on other tests
7)Subjects who cannot agree that surgery may be required if capsule endoscope retained in the body
8) Subjects whom otherwise the investigator determined ineligible as the subject
Target sample size
33
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kazuhide Higuchi |
Organization
Osaka Medical College
Division name
Second Department of Internal Medicine
Zip code
Address
2-7 Daigakumachi Takatsuki Osaka 569-8686 Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Eiji Umegaki |
Organization
Osaka Medical College
Division name
Second Department of Internal Medicine
Zip code
Address
2-7 Daigakumachi Takatsuki Osaka 569-8686 Japan
TEL
Homepage URL
Sponsor or person
Institute
Second Department of Internal Medicine, Osaka Medical College
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 12 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2011 | Year | 09 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 12 | Month | 10 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 12 | Month | 04 | Day |
Last modified on
| 2012 | Year | 12 | Month | 04 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011123
